Rehan Haider, Anjum Zehra, Asghar Mehdi, Geetha Kumari Das, Zameer Ahmed and Sambreen Zameer
Musculoskeletal disorders encompass a general range of conditions that move the cartilage, muscles, cheap hangouts, ligaments, and tendons, providing important challenges to patients and healthcare providers. Drug remedies play an important role in the treatment of these disorders, helping to lessen pain, reduce redness, upgrade mobility, and avoid affliction progress. This comprehensive review examines various arrays of drugs commonly used in the treatment of musculoskeletal disorders, including nonsteroidal anti-instigative drugs (NSAIDs), analgesics, corticosteroids, ailment- modifying antirheumatic drugs (DMARDs), and drug powers. Nonsteroidal antagonistic-inflammatory drugs (NSAIDs) are known for their anesthetic and antagonistic-inflammatory properties, providing relief in environments similar to osteoarthritis and rheumatoid arthritis. Analgesics containing acetaminophen and opioids are prescribed to control pain and guide musculoskeletal disorders, although opioid use is progressively being checked due to concerns regarding enslavement and antagonistic effects. Corticosteroids exhibit forceful antagonistic-instigative effects and are usually administered via an event-articular needle or spoken route for the management of severe exacerbations of angering joint diseases. Disease-reducing antirheumatic drugs (DMARDs) and drug powers target particular pathways complicated by autoimmune-mediated musculoskeletal disorders, contributing to affliction-lessening effects and reconstructing enduring outcomes. This review provides information on the systems of action, productiveness, security profiles, and dispassionate concerns of these drug classes, aiding informed administration in the treatment of musculoskeletal disorders. Moreover, emerging healing approaches and future guidance on drug use are discussed, with an emphasis on the development of pharmacotherapy in musculoskeletal care.